Guidelines for Accurate Diagnosis of Clostridioides difficile Infection in Acute Diarrhea

Test Sensitivity and Performance

• Toxin enzyme immunoassays (EIA) have the lowest sensitivity, detecting only ≈ 66 %–73 % of true C. difficile infections, which leads to a high false‑negative rate. 1, 2
• Nucleic acid amplification tests (NAAT/PCR) are more sensitive (≈ 93 %–94 %) but still miss about 5 %–10 % of true cases, corresponding to a false‑negative rate of roughly 6 %–7 %. 1, 2
• Multi‑step algorithms that combine glutamate dehydrogenase (GDH) screening with toxin detection and resolve discordant results by NAAT increase overall diagnostic sensitivity and are preferred over stand‑alone toxin testing. 3, 1

Recommended Testing Strategies

• For optimal sensitivity in patients with acute watery diarrhea, use either NAAT alone or a multi‑step algorithm (GDH + toxin, GDH + toxin arbitrated by NAAT, or NAAT + toxin) rather than toxin‑only testing. 3, 1
• Institutional testing criteria should require at least 3 unformed stools within a 24‑hour period before a specimen is collected. 3, 1
• Testing should be avoided in patients who have received laxatives, as laxative use markedly increases the risk of false‑positive results. 3

Repeat Testing and Clinical Management

• When clinical suspicion remains high—such as in patients whose symptoms worsen despite an initial negative result—repeat testing is warranted. 1, 4
• New or markedly changed diarrhea characteristics, or the emergence of additional supporting clinical evidence, also justify repeat testing. 1
• In epidemic or outbreak settings where C. difficile acquisition is more common, clinicians should have a lower threshold for repeat testing. 1, 4
• Routine repeat testing within 7 days of the original specimen is not recommended because the diagnostic yield is only about 2 % and it raises the likelihood of false‑positive results. 1, 4

Critical Pitfalls to Avoid

• Do not initiate empirical C. difficile therapy before collecting a stool specimen when testing is planned, as early treatment markedly increases false‑negative rates. (supported by the cited literature)
• Do not perform a test‑of‑cure after completing therapy; more than 60 % of patients who are clinically cured remain stool‑test positive, providing no useful information for management. 4
• Do not repeat testing within 7 days of the same diarrheal episode unless there is a significant change in the clinical picture. 1, 4
• Do not test asymptomatic individuals except for epidemiologic surveillance studies, as testing in the absence of symptoms yields low clinical value. 3, 4

Indications and Contraindications for Clostridioides difficile Testing

Indications for Testing

• The IDSA/SHEA guidelines recommend ordering C. difficile testing when a patient presents with new‑onset, unexplained diarrhea and has ≥ 3 unformed (loose or watery) stools within a 24‑hour period. This is a strong recommendation. 5

• Testing should be performed only if the diarrhea is recent and lacks an obvious alternative cause (e.g., known gastrointestinal infection, inflammatory disease). 6

• Patients must not have received laxatives in the preceding 24–48 hours, because laxative use markedly increases false‑positive results. This is a strong recommendation. 7

Age‑Specific Testing Guidance

• Infants ≤ 12 months should never be tested for C. difficile because asymptomatic colonization rates are high (≈ 50‑70%). This is a strong recommendation. 8

• Children 1–2 years old: testing is appropriate only after other infectious and non‑infectious causes of diarrhea have been excluded. 9

• Children ≥ 2 years old: testing is indicated when diarrhea is prolonged or worsening and the child has risk factors (e.g., inflammatory bowel disease, immunocompromise) or relevant exposures (recent healthcare contact, recent antibiotics). 9

Situations to Avoid Testing

• Asymptomatic individuals (no diarrhea) should not be tested; detecting colonization provides no clinical benefit aside from epidemiologic surveillance. This is a strong recommendation. 10

• Repeat testing within 7 days of the same diarrheal episode yields a diagnostic benefit of only ~2 % and raises the risk of false‑positive results; therefore it is discouraged. This is a strong recommendation. 8

• Testing of formed stools is inappropriate; only unformed/liquid stools should be submitted for analysis.

Strategies to Reduce Inappropriate Testing

• Implement computerized order‑entry restrictions that require documentation of ≥ 3 unformed stools and confirmation of no recent laxative use; such interventions have been shown to cut inappropriate testing by roughly two‑thirds without harming patient outcomes. 7

• Institutional protocols should automatically block C. difficile test orders for patients currently receiving laxatives, thereby preventing a common source of false‑positive results. 7

C. difficile Diagnostic Testing Algorithm for Immunocompromised Patients

Recommended Testing Strategy

• Use a multi‑step algorithm that begins with a GDH antigen screen, adds a toxin A/B enzyme immunoassay (EIA), and reflexes to nucleic‑acid amplification testing (NAAT) only when GDH and toxin results are discordant (GDH⁺/toxin⁻ or GDH⁻/toxin⁺). This approach is preferred over using NAAT alone or toxin EIA alone. [11][12]

Initial Screening: GDH Antigen Test

• Order a GDH enzyme immunoassay as the first‑line screening test for patients with ≥3 unformed stools. A negative GDH result effectively rules out C. difficile infection, allowing testing to be stopped. 11

Second Step: Toxin A/B EIA (performed when GDH is positive)

• Perform a toxin A/B EIA on the same specimen as the GDH test.
  
  • If both GDH and toxin are positive (GDH⁺/toxin⁺), the result is considered a definitive positive for CDI; no further testing is required. [11][12]
  • If GDH is positive but toxin is negative (GDH⁺/toxin⁻), reflex NAAT should be performed. [11][12]

Reflex Testing: NAAT for Discordant Results

• Conduct a PCR targeting the tcdB gene when GDH and toxin results are discordant. A positive NAAT after a GDH⁺/toxin⁻ result is interpreted as a positive finding, but clinical correlation is essential before confirming CDI. 11

Avoiding Inappropriate Use of NAAT

• Do not rely on NAAT alone in immunocompromised patients without clinical correlation, because NAAT cannot differentiate colonization from active infection. [11][12]

Performance Characteristics of the Multi‑Step Algorithm

These values are derived from studies evaluating the combined GDH + toxin + reflex NAAT approach. The algorithm balances the high sensitivity of NAAT with the high specificity of toxin detection, thereby reducing over‑diagnosis of colonization while preserving an excellent negative predictive value. [12][11]*